Current Advances in Allosteric Modulation of Muscarinic Receptors
Open accessThe DOI matches its Crossref record; 91 of the 92 references it cites were found in a registry or an index.
Abstract
Allosteric modulators are ligands that bind to a site on the receptor that is spatially separated from the orthosteric binding site for the endogenous neurotransmitter. Allosteric modulators modulate the binding affinity, potency, and efficacy of orthosteric ligands. Muscarinic acetylcholine receptors are prototypical allosterically-modulated G-protein-coupled receptors. They are a potential therapeutic target for the treatment of psychiatric, neurologic, and internal diseases like schizophrenia, Alzheimer’s disease, Huntington disease, type 2 diabetes, or chronic pulmonary obstruction. Here, we reviewed the progress made during the last decade in our understanding of their mechanisms of binding, allosteric modulation, and in vivo actions in order to understand the translational impact of studying this important class of pharmacological agents. We overviewed newly developed allosteric modulators of muscarinic receptors as well as new spin-off ideas like bitopic ligands combining allosteric and orthosteric moieties and photo-switchable ligands based on bitopic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 An orthosteric ligand L binds to the receptor R with equilibrium dissociation constant KD, and an allosteric modulator A binds to the receptor R with an equilibrium dissociation constant KA. The orthosteric ligand L and the allosteric modulator A can bind concurrently to the receptor R to form a ternary complex LRA. Binding of one ligand to the receptor changes the equilibrium dissociation constant of the other ligand by a factor of cooperativity α [15].](https://figures.cochat.ai/paper-figures/b8848fd3264b44ec85a45661d45fb5e7/current-advances-in-allosteric-modulation-of-muscarinic-receptors-figure-1.jpg)









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Allosteric modulators typically attach to regions distinct from the orthosteric site of receptors, inducing conformational changes to regulate the affinity and/or efficacy of orthosteric ligands, or to directly modulate receptor activity with positive, negative, or neutral effects.542–545”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [542]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
On the nature of allosteric transitions: A plausible model
Monod, J., Wyman, J., & Changeux, J.-P. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80285-6 · Cited by 8,825 · cited 2×
“The concept of allosterism was formally introduced into the field of enzymology by Monod et al.[13] and Koshland et al.”
BackgroundComparison of Experimental Binding Data and Theoretical Models in Proteins Containing Subunits*
Koshland, D. E., Némethy, G., & Filmer, D. (1966) · Biochemistry · doi:10.1021/bi00865a047 · Cited by 3,013
Ballesteros, J. A., & Weinstein, H. (1995) · Methods in Neurosciences · doi:10.1016/s1043-9471(05)80049-7 · Cited by 2,999
Identification of a Family of Muscarinic Acetylcholine Receptor Genes
Bonner, T. I., Buckley, N. J., Young, A. C., & Brann, M. R. (1987) · Science · doi:10.1126/science.3037705 · Cited by 1,427 · cited 1×
“Five distinct subtypes of muscarinic acetylcholine receptors (M1-M5) have been identified in the human genome[1].”
BackgroundActivation and allosteric modulation of a muscarinic acetylcholine receptor
Kruse, A. C., Ring, A. M., Manglik, A., Hu, J., Hu, K., Eitel, K., Hübner, H., Pardon, E., Valant, C., Sexton, P. M., et al. (2013) · Nature · doi:10.1038/nature12735 · Cited by 893 · cited 6×
“The availability of the M2 receptor crystal structure in an inactive [2], as well as active conformation [4] and advances in computer modeling, has allowed for the acceleration of structurebased design of chemically diverse allosteric modulators of this receptor [79].”
BackgroundInfluentialStructure and dynamics of the M3 muscarinic acetylcholine receptor
Kruse, A. C., Hu, J., Pan, A. C., Arlow, D. H., Rosenbaum, D. M., Rosemond, E., Green, H. F., Liu, T., Chae, P. S., Dror, R. O., et al. (2012) · Nature · doi:10.1038/nature10867 · Cited by 811 · cited 1×
“Interaction of orthosteric ligands with the allosteric domain between the o2 and o3 loops has been confirmed and studied in detail by computer modeling [3,58,59].”
BackgroundStructure of the human M2 muscarinic acetylcholine receptor bound to an antagonist
Haga, K., Kruse, A. C., Asada, H., Yurugi-Kobayashi, T., Shiroishi, M., Zhang, C., Weis, W. I., Okada, T., Kobilka, B. K., Haga, T., et al. (2012) · Nature · doi:10.1038/nature10753 · Cited by 792 · cited 2×
“The availability of the M2 receptor crystal structure in an inactive [2], as well as active conformation [4] and advances in computer modeling, has allowed for the acceleration of structure-based design of chemically diverse allosteric modulators of this receptor [79].”
BackgroundSignalling bias in new drug discovery: detection, quantification and therapeutic impact
Kenakin, T., & Christopoulos, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3954 · Cited by 740 · cited 1×
“This preferential orientation of the signaling of a GPCR towards a subset of its signal transducers is termed signaling bias[45].”
BackgroundMash, D. C., Flynn, D. D., & Potter, L. T. (1985) · Science · doi:10.1126/science.3992249 · Cited by 698 · cited 2×
“Encouragingly, post-synaptic receptors are relatively intact in neurod g nerative diseases like Alzheimer’s disease or senil dementia of Lewy b y typ [21,22].”
BackgroundHow Ligands Illuminate GPCR Molecular Pharmacology
Wacker, D., Stevens, R. C., & Roth, B. L. (2017) · Cell · doi:10.1016/j.cell.2017.07.009 · Cited by 560
Mechanisms and Physiological Significance of the Cholinergic Control of Pancreatic β-Cell Function
Gilon, P., & Henquin, J.-C. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.5.0440 · Cited by 508 · cited 1×
“Parasympathetic activation of pancreatic β cells by acetylcholine stimulates the release of insulin[83].”
BackgroundGeneric GPCR residue numbers – aligning topology maps while minding the gaps
Isberg, V., de Graaf, C., Bortolato, A., Cherezov, V., Katritch, V., Marshall, F. H., Mordalski, S., Pin, J.-P., Stevens, R. C., Vriend, G., et al. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.11.001 · Cited by 492 · cited 2×
“50 in the middle of the o3 loop (general GPCR numbering [32,33]).”
BackgroundStructural basis for modulation of a G-protein-coupled receptor by allosteric drugs
Dror, R. O., Green, H. F., Valant, C., Borhani, D. W., Valcourt, J. R., Pan, A. C., Arlow, D. H., Canals, M., Lane, J. R., Rahmani, R., et al. (2013) · Nature · doi:10.1038/nature12595 · Cited by 411 · cited 1×
“Computer modelling studies of allosteric ligand binding to M2 receptors revealed two centers for binding of the electropositive part of allosteric ligands (Figure 3)[24].”
BackgroundMuscarinic receptor signaling in the pathophysiology of asthma and COPD
Gosens, R., Zaagsma, J., Meurs, H., & Halayko, A. J. (2006) · Respiratory Research · doi:10.1186/1465-9921-7-73 · Cited by 409
Crystal structures of the M1 and M4 muscarinic acetylcholine receptors
Thal, D. M., Sun, B., Feng, D., Nawaratne, V., Leach, K., Felder, C. C., Bures, M. G., Evans, D. A., Weis, W. I., Bachhawat, P., et al. (2016) · Nature · doi:10.1038/nature17188 · Cited by 335
Hermans, E. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00051-2 · Cited by 327
Laugwitz, K. L., Allgeier, A., Offermanns, S., Spicher, K., Van Sande, J., Dumont, J. E., & Schultz, G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.116 · Cited by 317
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders
Conn, P. J., Jones, C. K., & Lindsley, C. W. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.12.002 · Cited by 286 · cited 1×
“, schizophrenia, Alzheimer’s disease, Huntington disease) [8,9] as well as internal diseases (e.”
BackgroundTHE INHIBITORY EFFECT OF GALLAMINE ON MUSCARINIC RECEPTORS
CLARK, A. L., & MITCHELSON, F. (1976) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1976.tb07708.x · Cited by 251 · cited 1×
“Later, Clark and Mitchelson discovered that gallamine similarly inhibited the action of acetylcholine and carbachol on the function of heart atria in a non-competitive manner [19].”
BackgroundMuscarinic receptors in the bladder: from basic research to therapeutics
Hegde, S. S. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706560 · Cited by 232
Jakubík, J., Bačáková, L., El-Fakahany, E. E., & Tuček, S. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.1.172 · Cited by 228 · cited 2×
“Although positive allosteric modulation of acetylcholine as resented as proof of concept in the 1990s [71,72], it took more than 10 years to develop first PAMs with physiol gically active pr perties suitable for further drug development [73–76].”
BackgroundSelf-citationDevelopment of allosteric modulators of GPCRs for treatment of CNS disorders
Nickols, H. H., & Conn, P. J. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.013 · Cited by 226 · cited 2×
“Thus, selective positive modulation of M4 receptors may provide a novel treatment strategy of psychotic symptoms in schizophrenia that are considered to result from dopaminergic hyperactivity [83].”
BackgroundInteraction of G protein coupled receptors and cholesterol
Gimpl, G. (2016) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2016.04.006 · Cited by 204 · cited 7×
“Many GPCRs, including muscarinic receptors, activate several signaling pathways upon activation by agonists [47–49].”
BackgroundInfluentialBrady, A. E., Jones, C. K., Bridges, T. M., Kennedy, J. P., Thompson, A. D., Heiman, J. U., Breininger, M. L., Gentry, P. R., Yin, H., Jadhav, S. B., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.140350 · Cited by 203
Duttaroy, A., Zimliki, C. L., Gautam, D., Cui, Y., Mears, D., & Wess, J. (2004) · Diabetes · doi:10.2337/diabetes.53.7.1714 · Cited by 199 · cited 1×
“Effects of acetylcholine on insulin secretion are mediated by the M3 receptor [91].”
BackgroundTzavara, E. T., Bymaster, F. P., Davis, R. J., Wade, M. R., Perry, K. W., Wess, J., McKinzie, D. L., Felder, C., & Nomikos, G. G. (2004) · The FASEB Journal · doi:10.1096/fj.04-1575fje · Cited by 191 · cited 1×
“The striatal M4 receptors attenuate dopaminergic and glutamatergic neurotransmission [85].”
BackgroundA Novel Mechanism of G Protein-coupled Receptor Functional Selectivity
Valant, C., Gregory, K. J., Hall, N. E., Scammells, P. J., Lew, M. J., Sexton, P. M., & Christopoulos, A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803801200 · Cited by 173 · cited 1×
“Mutations of the allosteric and orthosteric binding sites revealed that NDMC (N-desmethylclozapine) that was considered an allosteric agonist and McN-A-343 (4-(m-chlorophenyl-carbamoyloxy)-2-butynyltri-methylammonium) that was considered an orthosteric agonist are in fact bitopic ligands[61,62].”
BackgroundGregory, K. J., Hall, N. E., Tobin, A. B., Sexton, P. M., & Christopoulos, A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.094011 · Cited by 159 · cited 3×
“Allosteric effects of the bitopic agonists McN-A-343 and NDMC and the all steric agonists AC-42 and 77-LH-28-1 (Figure 6) are mediated via Y177 in the o2 loop of the M2 receptor [66].”
BackgroundInfluentialMarlo, J. E., Niswender, C. M., Days, E., Bridges, T. M., Xiang, Y., Rodriguez, A. L., Shirey-Rice, J. K., Brady, A. E., Nalywajko, T., Luo, Q., et al. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.052886 · Cited by 159
Muscarinic Receptor Antagonists: Effects on Pulmonary Function
Buels, K. S., & Fryer, A. D. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-23274-9_14 · Cited by 151 · cited 2×
“, bronchospasm in asthma [23]) or overstimulation of salivary and lacrimal glands after organophosphate poisoning in case of M3-selective PAMantagonists.”
BackgroundMuscarinic modulation of striatal function and circuitry
Goldberg, J. A., Ding, J. B., & Surmeier, D. J. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-23274-9_10 · Cited by 150 · cited 1×
“Cholinergic neurons regulate glutamatergic neurons in the striatum that regulate selection and decision-making behavior [81].”
BackgroundOverview of Muscarinic Receptor Subtypes
Eglen, R. M. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-23274-9_1 · Cited by 136 · cited 7×
“M5 muscarinic receptors are expressed solely in the substantia nigra and ventral tegmental area (VTA) [7].”
BackgroundInfluentialPerry, E. K., Smith, C. J., COURT, J. A., & Perry, R. H. (1990) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02257646 · Cited by 124 · cited 2×
“Encouragingly, post-synaptic receptors are relatively intact in neurod g nerative diseases like Alzheimer’s disease or senil dementia of Lewy b y typ [21,22].”
BackgroundActivation of muscarinic acetylcholine receptors via their allosteric binding sites.
Jakubík, J., Bačáková, L., Lisá, V., El‐Fakahany, E. E., & Tucek, S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8705 · Cited by 109 · cited 1×
“NAM-agonists that possess own agonistic propensity in the absence of the agonists and activate the receptor, while they negatively modulate endogenous agonist [17]; 6.”
BackgroundSelf-citationBridges, T. M., Marlo, J. E., Niswender, C. M., Jones, C. K., Jadhav, S. B., Gentry, P. R., Plumley, H. C., Weaver, C. D., Conn, P. J., & Lindsley, C. W. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900286j · Cited by 107
Analogs of WIN 62,577 Define a Second Allosteric Site on Muscarinic Receptors
Lazareno, S., Popham, A., & Birdsall, N. J. M. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.6.1492 · Cited by 105
Ligand Binding Ensembles Determine Graded Agonist Efficacies at a G Protein-coupled Receptor
Böck, A., Bermúdez, M., Krebs, F., Matera, C., Chirinda, B., Sydow, D., Dallanoce, C., Holzgrabe, U., Amici, M. D., Lohse, M. J., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.735431 · Cited by 104 · cited 2×
“A combination of the nonselective muscarinic agonis iperoxo and its M1-selective PAM BQCA has led to a set of M1-selective ag nists with graded efficacy that is dependent n the chemical tru tur of the linker [62].”
BackgroundLeppik, R. A., Miller, R. C., Eck, M., & Paquet, J. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10214-9 · Cited by 92 · cited 1×
“The charged EDGE motif in the o2 loop plays a critical role in the binding of these ligands [27].”
BackgroundAllosteric modulators targeting CNS muscarinic receptors
Böck, A., Schrage, R., & Mohr, K. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.024 · Cited by 91 · cited 1×
“, schizophrenia, Alzheimer’s disease, Huntington disease) [8,9] as well as internal diseases (e.”
BackgroundMiao, Y., Goldfeld, D. A., Moo, E. V., Sexton, P. M., Christopoulos, A., McCammon, J. A., & Valant, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612353113 · Cited by 89
Isomerization of the muscarinic receptor . antagonist complex.
Järv, J., Hedlund, B., & Bartfai, T. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)50452-x · Cited by 83 · cited 1×
“The model in which an orthosteric ligand binds transiently to a secondary site before moving to the orthosteric binding site (so-called tandem two-site model [55]) has been proposed to explain apparent receptor isomerization upon antagonist binding [56,57].”
BackgroundM1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss
Bradley, S. J., Bourgognon, J.-M., Sanger, H. E., Verity, N., Mogg, A. J., White, D. J., Butcher, A. J., Moreno, J. A., Molloy, C., Macedo-Hatch, T., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87526 · Cited by 81 · cited 1×
“The site is preferentially formed at the M1 receptor and has been identified as a binding site of highly M1-selective PAM BQZ12 (Figure 4) [34,35].”
BackgroundKorczynska, M., Clark, M. J., Valant, C., Xu, J., Moo, E. V., Albold, S., Weiss, D. R., Torosyan, H., Huang, W., Kruse, A. C., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718037115 · Cited by 81
Crystal structure of the M 5 muscarinic acetylcholine receptor
Vuckovic, Z., Gentry, P. R., Berizzi, A. E., Hirata, K., Varghese, S., Thompson, G., van der Westhuizen, E. T., Burger, W. A. C., Rahmani, R., Valant, C., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914446116 · Cited by 80 · cited 1×
“Subtype variations of affinity and kinetics of orthosteric ligands may be attributed to variation in their interaction with the allosteric site [6].”
BackgroundLüllmann, H., Ohnesorge, F. K., Schauwecker, G.-C., & Wassermann, O. (1969) · European Journal of Pharmacology · doi:10.1016/0014-2999(69)90181-2 · Cited by 79 · cited 2×
“showed in their pioneering work that alkane-bis-ammonium compounds inhibited the functional response to the conventional muscarinic agonist carbachol non-competitively [18].”
BackgroundA Photoswitchable Dualsteric Ligand Controlling Receptor Efficacy
Agnetta, L., Kauk, M., Cañizal, M. C. A., Messerer, R., Holzgrabe, U., Hoffmann, C., & Decker, M. W. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201701524 · Cited by 79 · cited 1×
“Further development of bitopic ligands has led to the discovery of the photo-switchable ligands [68].”
BackgroundGentry, P. R., Kokubo, M., Bridges, T. M., Kett, N. R., Harp, J. M., Cho, H. P., Smith, E. W., Chase, P. S., Hodder, P., Niswender, C. M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4013246 · Cited by 77
Role of the M 3 muscarinic acetylcholine receptor in β‐cell function and glucose homeostasis
Gautam, D., Han, S. ‐., Duttaroy, A., Mears, D., Hamdan, F. F., Li, J. H., Cui, Y., Jeon, J., & Wess, J. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00781.x · Cited by 74
PAM-Antagonists: A Better Way to Block Pathological Receptor Signaling?
Kenakin, T., & Strachan, R. T. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.05.001 · Cited by 74 · cited 2×
“PAM-antagonists that exhibit partial or absolute selectivity for a given receptor subtype may be used to selectively target receptors activated by the endogenous neurotransmitter located in specific tissues or organs [16].”
BackgroundCryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs
Hollingsworth, S. A., Kelly, B., Valant, C., Michaelis, J. A., Mastromihalis, O., Thompson, G., Venkatakrishnan, A. J., Hertig, S., Scammells, P. J., Sexton, P. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11062-7 · Cited by 73 · cited 2×
“A cryptic allosteric binding pocket in the extr cellular domain that is absent in isting cry tal structures has been predicted by simulation of molecular dynamics a d confirmed by mutagenesis experi ents [31].”
BackgroundMethodNawaratne, V., Leach, K., Felder, C. C., Sexton, P. M., & Christopoulos, A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.125096 · Cited by 70 · cited 3×
“In contrast, M4-selective PAM LY2033298 (Figure 4) interacts with the o1, o2, and o3 loops [30].”
BackgroundInfluentialKuduk, S. D., Chang, R. K., Marco, C. N. D., Pitts, D. R., Greshock, T. J., Ma, L., Wittmann, M., Seager, M. A., Koeplinger, K. A., Thompson, C. D., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200400m · Cited by 66
Avlani, V. A., Langmead, C. J., Guida, E., Wood, M. D., Tehan, B. G., Herdon, H. J., Watson, J. M., Sexton, P. M., & Christopoulos, A. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064345 · Cited by 65 · cited 2×
“Another example of a bitopic agonist that gains its selectivity from interaction with the common allosteric binding site is TBPB (Figure 6) [64,65].”
BackgroundMolecular Determinants of Allosteric Modulation at the M1 Muscarinic Acetylcholine Receptor
Abdul-Ridha, A., López, L., Keov, P., Thal, D. M., Mistry, S. N., Sexton, P. M., Lane, J. R., Canals, M., & Christopoulos, A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.539080 · Cited by 62 · cited 3×
“M1-selective PAM benzyl quinolone carboxylic acid (BQCA, Figure 4) binds to Y179 and F182 in the o2 loop, and E397 and W400 in TM7 [29].”
BackgroundNj, B., Farries, T., Gharagozloo, P., Kobayashi, S., Kuonen, D. R., Lazareno, S., Popham, A., & Sugimoto, M. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00046-5 · Cited by 59
Toward an understanding of the structural basis of allostery in muscarinic acetylcholine receptors
Burger, W. A. C., Sexton, P. M., Christopoulos, A., & Thal, D. M. (2018) · The Journal of General Physiology · doi:10.1085/jgp.201711979 · Cited by 59
Huang, X., Prilla, S., Mohr, K., & Ellis, J. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014043 · Cited by 57 · cited 1×
“The binding site of classical allosteric modulators like gallamine, alcuronium or alkane-bisammonium compounds has been located between the second (o2) and third extracellular (o3) loops (Figure 2, green) [21,22].”
BackgroundAbdul-Ridha, A., Lane, J. R., Mistry, S. N., López, L., Sexton, P. M., Scammells, P. J., Christopoulos, A., & Canals, M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.604967 · Cited by 56 · cited 2×
“The site is preferentially formed at the M1 receptor and has been identified as a binding site of highly M1-selective PAM BQZ12 (Figure 4) [34,35].”
BackgroundJakubík, J., El‐Fakahany, E. E., & Doležal, V. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.023762 · Cited by 54
Self-citationMuscarinic Receptors in Brain Stem and Mesopontine Cholinergic Arousal Functions
Yeomans, J. S. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-23274-9_11 · Cited by 51 · cited 2×
“is sitive fee back orks as the re ard circuit [87].”
BackgroundPancani, T., Foster, D. J., Moehle, M. S., Bichell, T. J., Bradley, E. M., Bridges, T. M., Klar, R., Poslusney, M., Rook, J. M., Daniels, J. S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512812112 · Cited by 51 · cited 1×
“In accordance, M4 PAMs have improved behavioral symptoms in the mouse model of Huntington disease [76].”
BackgroundAllosteric Modulation of Muscarinic Acetylcholine Receptors
Jakubík, J., & El‐Fakahany, E. E. (2010) · Pharmaceuticals · doi:10.3390/ph3092838 · Cited by 50
Self-citationKrejčı́, A., & Tucek, S. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12303-6 · Cited by 49
Mistry, S. N., Jörg, M., Lim, H. D., Vinh, N. B., Sexton, P. M., Capuano, B., Christopoulos, A., Lane, J. R., & Scammells, P. J. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01562 · Cited by 48 · cited 1×
“Similarly, derivatives of 4-phenylpyridin-2-one (Figure 8) display a diverse range of activities, ranging from pure PAMs to pure allosteric agonists [78].”
BackgroundEvidence for a Tandem Two-site Model of Ligand Binding to Muscarinic Acetylcholine Receptors
Jakubík, J., El‐Fakahany, E. E., & Tuček, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000112200 · Cited by 44 · cited 1×
“The model in which an orthosteric ligand binds transiently to a secondary site before moving to the orthosteric binding site (so-called tandem two-site model [55]) has been proposed to explain apparent receptor isomerization upon antagonist binding [56,57].”
BackgroundSelf-citationDualsteric Muscarinic Antagonists–Orthosteric Binding Pose Controls Allosteric Subtype Selectivity
Schmitz, J., van der Mey, D., Bermúdez, M., Klöckner, J., Schrage, R., Kostenis, E., Tränkle, C., Wolber, G., Mohr, K., & Holzgrabe, U. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500790x · Cited by 38 · cited 2×
“The rientation of the orthosteric moiety within the orthosteric bin ing sit is crucial for subtype selectivity [63].”
BackgroundGunter, B. W., Gould, R. W., Bubser, M., McGowan, K. M., Lindsley, C. W., & Jones, C. K. (2017) · Addiction Biology · doi:10.1111/adb.12567 · Cited by 38 · cited 3×
“The l ti A of acetylcholine ML375 (Figure 9) [88] has effectively prevented cocaine selfadministration and the development of addiction in rats [89].”
BackgroundInfluentialCristofaro, I., Spinello, Z., Matera, C., Fiore, M., Conti, L., Amici, M. D., Dallanoce, C., & Tata, A. M. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.04.010 · Cited by 37 · cited 3×
“naphmethonium or W84) can be used as non-opioid non-steroidal analgesics [69] or inhibitors of cell growth for glioblastoma therapy [70].”
BackgroundMethodInterfacial Binding Sites for Cholesterol on G Protein-Coupled Receptors
LEE, A. G. J. (2019) · Biophysical Journal · doi:10.1016/j.bpj.2019.03.025 · Cited by 36 · cited 14×
“64 in the o2 loop close to TM2, and conserved 45.50 i iddle of the o3 lo p (general GPCR numbering [32,33]).”
BackgroundInfluentialZhu, L., Rossi, M., Cohen, A. H., Pham, J., Zheng, H., Dattaroy, D., Mukaibo, T., Melvin, J. E., Langel, J., Hattar, S. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904943116 · Cited by 36
Keov, P., Valant, C., Devine, S. M., Lane, J. R., Scammells, P. J., Sexton, P. M., & Christopoulos, A. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.087320 · Cited by 35 · cited 2×
“Another example of a bitopic agonist that gains its selectivity from interaction with the common allosteric binding site is TBPB (Figure 6) [64,65].”
BackgroundDavie, B. J., Valant, C., White, J. M., Sexton, P. M., Capuano, B., Christopoulos, A., & Scammells, P. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500556a · Cited by 32
Kinetic studies on muscarinic antagonist-agonist competition.
Järv, J., Hedlund, B., & Bartfai, T. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85782-4 · Cited by 31
Binding of Orthosteric Ligands to the Allosteric Site of the M2 Muscarinic Cholinergic Receptor
Redka, D. S., Pisterzi, L. F., & Wells, J. W. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.048074 · Cited by 31 · cited 1×
“Interaction of orthosteric ligands with the allosteric domain between the o2 and o3 loops has been confirmed and studied in detail by computer modeling [3,58,59].”
BackgroundMichal, P., Rudajev, V., El‐Fakahany, E. E., & Doležal, V. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.01.028 · Cited by 30
Self-citationDoes Divergent Binding Pocket Closure Drive Ligand Bias for Class A GPCRs?
Bermúdez, M., & Böck, A. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.02.005 · Cited by 29 · cited 8×
“Many GPCRs, including muscarinic receptors, activate several signaling pathways upon activation by agonists [47–49].”
BackgroundInfluentialMatera, C., Flammini, L., Quadri, M., Vivo, V., Ballabeni, V., Holzgrabe, U., Mohr, K., Amici, M. D., Barocelli, E., Bertoni, S., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.032 · Cited by 28 · cited 3×
“naphmethonium or W84) can be used as non-opioid non-steroidal analgesics [69] or inhibitors of cell growth for glioblastoma therapy [70].”
BackgroundMethodChoy, K. H. C., Shackleford, D. M., Malone, D. T., Mistry, S. N., Patil, R. T., Scammells, P. J., Langmead, C. J., Pantelis, C., Sexton, P. M., Lane, J. R., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235788 · Cited by 28
Bermúdez, M., & Wolber, G. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.03.026 · Cited by 27 · cited 1×
“This hypothesis was confirmed later by crystal structures and molecular modeling [4,44].”
Jakubík, J., Krejčı́, A., & Doležal, V. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.080358 · Cited by 25
Zlotos, D. P., Buller, S., Stiefl, N., Baumann, K., & Mohr, K. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0311341 · Cited by 23 · cited 1×
“Comparison of the binding cooperativity of a given allosteric ligand with several orthosteric ligands has suggested that cooperativity is dependent on the distance between the electropositive and electronegative part of the orthosteric ligand [43].”
BackgroundMolecular Mechanisms of Methoctramine Binding and Selectivity at Muscarinic Acetylcholine Receptors
Jakubík, J., Zimčík, P., Randáková, A., Fuksová, K., El‐Fakahany, E. E., & Doležal, V. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.093310 · Cited by 22
Self-citationDallagnol, J. C. C., Khajehali, E., van der Westhuizen, E. T., Jörg, M., Valant, C., Gonçalves, A. G., Capuano, B., Christopoulos, A., & Scammells, P. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01812 · Cited by 22
Hopper, S., Pavey, G., Gogos, A., & Dean, B. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz045 · Cited by 22
Michal, P., El‐Fakahany, E. E., & Doležal, V. (2014) · Neurochemical Research · doi:10.1007/s11064-014-1325-z · Cited by 18
Self-citationvan der Westhuizen, E. T., Spathis, A., Khajehali, E., Jörg, M., Mistry, S. N., Capuano, B., Tobin, A. B., Sexton, P. M., Scammells, P. J., Valant, C., et al. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.111633 · Cited by 18 · cited 1×
“However, structurally divergent M1 PAMs BQCA (Figure 4) and MIPS1674 (Figure 5) have shown only small differences in the modulation of the inositol phosphate, β-arrestin, and ERK1/2 pathways [52].”
BackgroundBinding of N-methylscopolamine to the extracellular domain of muscarinic acetylcholine receptors
Jakubík, J., Randáková, A., Zimčík, P., El‐Fakahany, E. E., & Doležal, V. (2017) · Scientific Reports · doi:10.1038/srep40381 · Cited by 17 · cited 1×
“Interaction of orthosteric ligands with the allosteric domain between the o2 and o3 loops has been confirmed and studied in detail by computer modeling [3,58,59].”
BackgroundSelf-citationSecond M3 muscarinic receptor binding site contributes to bronchoprotection by tiotropium
Kistemaker, L. E. M., Elzinga, C. R. S., Tautermann, C. S., Pieper, M. P., Seeliger, D., Alikhil, S., Schmidt, M., Meurs, H., & Gosens, R. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14707 · Cited by 17 · cited 1×
“The strong interaction of tiotropium with the allosteric binding site also explains the discrepancy between extremely slow binding kinetics and immediate inhibitory action of this bronchodilator [60].”
BackgroundJanickova, H., Rudajev, V., Dolejsi, E., Koivisto, H., Jakubik, J., Tanila, H., El-Fakahany, E., & Dolezal, V. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666151027130350 · Cited by 15
Self-citationRandáková, A., Dolejší, E., Rudajev, V., Zimčík, P., Doležal, V., El‐Fakahany, E. E., & Jakubík, J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.027 · Cited by 15 · cited 1×
“Using site-directed mutagenesis, the binding site for membrane cholesterol has been located to the groove between TM6 and TM7 in the intracellular leaflet of the membrane [40].”
Self-citationAllosteric Modulation of Muscarinic Receptors
Jakubík, J., & El‐Fakahany, E. E. (2015) · Neuromethods · doi:10.1007/978-1-4939-2858-3_6 · Cited by 4 · cited 3×
“modulators induces a change in the conformation of the receptor that results in changes in affinity (eventually potency and efficacy) of the orthosteric ligand [15].”
BackgroundSelf-citation
Research works printed but not linked: 1
- Ballesteros, 1995, Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors, Methods Neurosci., 25, 366, 10.1016/s1043-9471(05)80049-7 · DOI · Paper page
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia
Paul, S. M., Yohn, S. E., Popiolek, M., Miller, A., & Felder, C. C. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21101083 · Cited by 165
Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease
Dwomoh, L., Tejeda, G. S., & Tobin, A. B. (2022) · Neuronal Signaling · doi:10.1042/ns20210004 · Cited by 60
Shpakov, A. O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076187 · Cited by 60
Yohn, S. E., Harvey, P. D., Brannan, S. K., & Horan, W. P. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1421554 · Cited by 40
“For instance, simulation of molecular dynamics have revealed cryptic allosteric binding pockets in the vicinity of the common allosteric binding site (28).”
Background
Metadata
- Authors
- Jakubik, J., & El-Fakahany, E. E.
- Affiliations
- Department of Neurochemistry, Institute of Physiology CAS, 142 20 Prague, Czech Republic
- Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN 55455, USA
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2020-02-18
- Volume
- 10
- Issue
- 2
- Pages
- 325
- ISSN
- 2218-273X (ISSN-L)
- PMC
- PMC7072599
- OpenAlex
- W3000377840
- Cited by
- 48
- References
- 92
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 12 · 2023: 8 · 2022: 7 · 2021: 6 · 2020: 4
- FWCI
- 0.62
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomolecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Grantová Agentura České Republiky (19-05318S)
- Akademie věd České Republiky (RVO:67985823)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Keywords
- muscarinic receptors, allosteric modulation, allosteric modulators, G protein-coupled receptors, bitopic ligands, orthosteric binding site, receptor binding mechanism, muscarinic agonists, antimuscarinic agents, schizophrenia, Alzheimer's disease, Huntington's disease, type 2 diabetes
- MeSH terms
- Allosteric Regulation, Animals, Binding Sites, Humans, Ligands, Receptors, Muscarinic, Muscarinic Agonists, Muscarinic Antagonists, Receptors, G-Protein-Coupled
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.